Jenex Corporate Update

Michael Jenkins, President & CEO of The Jenex Corporation Reports

FOR IMMEDIATE RELEASE

July 10, 2002

Burlington, Ontario

THE JENEX CORPORATION (“Jenex” or the “Corporation”) (TSX Venture Exchange – JEN) recently issued a press release outlining the feedback the corporation received from FDA. Subsequently we have had many phone calls and emails requesting additional information and I believe it is prudent to update all concerned via this communiqué.

 Although we were somewhat surprised and disappointed we did not receive clearance to market in the USA at this time; I am confident we will complete and submit the required information and ultimately be successful with our prevention claim. A plan of action was developed after our teleconference with FDA and our professional advisors are now determining the time frame required to complete the process.

 The Corporation is pushing forward with their European Regulatory approvals and private placement opportunities. We will actively pursue a qualified partner to market our device(s) in Canada where we have been approved for the cold sore prevention claim.

Our original corporate plan had a three to five year timetable to allow management the requisite time to execute the business plan and create maximum value for our shareholders. I believe we will achieve our corporate objectives within this timetable.

                           “Prevention is the Solution”

The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the accuracy or the contents of this press release.

                            The Jenex Corporation

207      -  940 Sheldon Court

                            Burlington, Ontario, L7L 5K6

                            Michael A. Jenkins, President

                            Telephone:  (905) 632-3830

                             Facsimile:  (905) 632-3774

                             Email:  jenex@sprint.ca

    Website:  www.jenexcorp.com